ESPR vs ACAD vs CVS vs MDGL

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 9x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +310. 1%, compared to -85. 9% for Esperion Therapeutics, Inc. (ESPR). Over 10 years, the gap is even starker: MDGL returned +39. 2% versus ESPR's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Esperion Therapeutics, Inc. 's 2. 33β — meaning ESPR is approximately 4504% more volatile than CVS relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, ESPR leads at 74. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ESPR leads at 15. 0% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, CVS Health Corporation (CVS) trades at 12.

2x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 38. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACAD: 54. 1% to $34. 78.

In this comparison, CVS (3.

1% yield) pays a dividend. ESPR, ACAD, MDGL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

05), 3. 1% yield). Esperion Therapeutics, Inc. (ESPR) carries a higher beta of 2. 33 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, ESPR: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ESPR is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; CVS is a mid-cap income-oriented stock; MDGL is a mid-cap high-growth stock. CVS pays a dividend while ESPR, ACAD, MDGL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.